Mitoxantrone Baxter

Mitoxantrone Baxter Side Effects

mitoxantrone

Manufacturer:

Baxter Oncology

Distributor:

Transmedic
Full Prescribing Info
Side Effects
Bone marrow depression can occur during mitoxantrone treatment even in the therapeutical dose range. In such a case, a drop in the leucocyte count is observed in the first place. In patients who have previously undergone chemotherapy and/or radiation therapy as well as in patients in a generally poor state of health, marked bone marrow depression can occur. The lowest leucocyte count is generally observed between 6 and 15 days after mitoxantrone administration. Subsequently, the bone marrow recovers and haematological parameters normalise which, as a rule, is completed by 21 days after administration. A severe thrombocytopenia and, even more rarely, a very low erythrocyte count are seldom observed.
Nausea and vomiting can occur temporarily. They are in most cases of mild to moderate severity. Loss of hair was observed in about 20% of the patients treated with mitoxantrone, which was reversible in most cases when the treatment was discontinued.
Cardiac side effects eg, transient ECG alterations, acute arrhythmia, reduced left ventricular ejection fraction as well as cases of cardiac insufficiency can occur after administration of mitoxantrone. These cardiac phenomena are observed particularly in high-risk patients (see Contraindications).
Patients with cardiac insufficiency generally respond well to a supportive treatment with digitalis and/or diuretic agents.
Occasionally, stomatitis and/or mucositis, in most cases of lower degree, can occur (in some cases more frequently and pronounced during treatment of leukaemia).
Occasionally, hypersensitivity reactions (hyperergias) are possible, which may appear as acute general allergic reactions (anaphylaxis) in exceptional cases.
Side effects eg, loss of appetite, diarrhoea, abdominal pain, constipation, gastrointestinal bleeding, tiredness and debility, amenorrhoea, fever, dyspnea and nonspecific neurological disorders are occasionally observed. However, a connection between neurological disorders and the administration of mitoxantrone could not be established so far.
Liver enzyme, serum creatinine and blood urea values may temporarily change in individual cases. Marked pathological alterations of the liver enzyme values and an impairment of liver function can occasionally occur in patients with acute leukaemia.
Isolated severe local reactions (necroses) have only been reported up to now after inadvertent paravenous injection.
Mitoxantrone causes a blue-green coloration of the urine for 1-2 days after administration. In rare cases, reversible blue-green coloration of the sclera, veins and perivenous tissue as well as the nails (including onycholysis) were observed.
In case of intrapleural instillation, pain and side effects similar to those after systemic application may occur.
The patient is requested to inform the doctor about all side effects not mentioned previously.
Treatment in Case of Side Effects: Bone Marrow Depression: Due to the severity of bone marrow depression, a consequent infection prophylaxis with antibiotics has to be initiated. To counteract agranulocytosis and thrombocytopenia, whole blood transfusions, leucocyte and thrombocyte concentrates are suitable. (See Dosage & Administration.)
Cardiac Side Effects: Patients with cardiac insufficiency generally respond well to a supportive treatment with digitalis and/or diuretic agents.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in